The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super‐enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis‐generating study

Abstract Background Inhibition of CDK7, a potent transcription regulator, may bring new hope for treating pancreatic ductal adenocarcinoma (PDAC), which is featured by large genetic heterogeneity and abundant KRAS mutations. This investigation aimed at exploring the discrepant efficacies of THZ1, a...

Full description

Bibliographic Details

Published in:	Clinical and Translational Medicine
Main Authors:	Lei Huang, Hui Yang, Kaidi Chen, Jing Yuan, Jie Li, Guanghai Dai, Mancang Gu, Yan Shi
Format:	Article
Language:	English
Published:	Wiley 2023-12-01
Subjects:	cyclin‐dependent kinase 7 KRAS mutants pancreatic ductal adenocarcinoma PI3K/AKT/mTOR signalling precision oncology RNA polymerase II
Online Access:	https://doi.org/10.1002/ctm2.1500